Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
5 hedge funds and large institutions have $574K invested in Loncar China BioPharma ETF in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
40% more capital invested
Capital invested by funds: $411K → $574K (+$163K)
25% more funds holding
Funds holding: 4 → 5 (+1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$49K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$33 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.4K |
| 2 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
-$2.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $560K | +$49K | +2,928 | +11% |
|
|
BBPWM
2
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $5.78K | -$2.36K | -141 | -31% |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.73K | -$14.4K | -859 | -77% |
|
4
Morgan Stanley
New York
| $3.53K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | +$33 | +2 | New |
|
CHNA Hedge Fund Activity: Q4 2022 in Review
5 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2022, worth a combined $574K — up 40% from $411K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CHNA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, adding an estimated $49K. The largest seller was UBS Group, cutting an estimated $14.4K.
- 5 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2022, up from 4 in Q3 2022.
- Funds reported $574K of Loncar China BioPharma ETF stock for Q4 2022, up 40% quarter-over-quarter.
- 1 fund opened new Loncar China BioPharma ETF positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest Loncar China BioPharma ETF buyer in Q4 2022 was Jane Street, an estimated $49K added.
- The largest Loncar China BioPharma ETF seller in Q4 2022 was UBS Group, an estimated $14.4K sold.
Based on aggregated 13F filings for Q4 2022.